A review of the second-generation antihistamine ebastine for the treatment of allergic disorders (Q28272998)

Expert Opinion on Pharmacotherapy

Europe PubMed Central

title

A review of the second-generation antihistamine ebastine for the treatment of allergic disorders (English)

0 references

1 reference

Paul Van Cauwenberge

1

0 references

Tine De Belder

series ordinal

2

0 references

Lien Sys

series ordinal

3

0 references

language of work or name

English

0 references

publication date

August 2004

0 references

published in

0 references

volume

5

0 references

issue

8

0 references

page(s)

1807-13

0 references

cites work

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval

1 reference

https://api.crossref.org/works/10.1517/14656566.5.8.1807

Allergic rhinitis and its impact on asthma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Therapeutic advantages of third generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Ebastine: an update of its use in allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Clinical pharmacology of new histamine H1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Comparative pharmacology of H1 antihistamines: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Duration of the antihistaminic effect after discontinuation of ebastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Comparative tolerability of second generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Cardiac actions of antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807

A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.8.1807